Excelimmune, Inc.

Description

Dr. Dahl joined Excelimmune, Inc. in 2013 as Vice President of Product Development. Tom has more than 20 years of experience in experimental therapeutics in both academia and biopharmaceutical industry, including product development, clinical trial design, execution and interpretation, as well as experience in data presentation to funding communities, analysts, and biotech and pharmaceutical partners. He has held senior management positions in a number of biotech companies, including CEO, COO and VP of Clinical Development.

He was President and CEO of Lotus Tissue Repair, which he co-founded in 2010 to develop recombinant collagen VII as protein replacement therapy for a devastating orphan genetic disease, dystrophic epidermolysis bullosa. Lotus Tissue Repair secured a $26 million Series A commitment from Third Rock Ventures in 2011. The company was acquired by Shire in early 2013.

Excelimmune is developing a new wave of Antibody Combination Therapeutics (ACT), which will become the new standard of care for monotherapy-resistant infectious and oncological diseases. The company's vision is to develop and produce multi-antibody therapeutics that mimic the effectiveness and resistance to escape mutants typically exhibited by the adaptive humoral immune response of a healthy, human being.

Products & services

Similar companies nearby